AMRN - Amarin Corp - ADR
IEX Last Trade
0.6322
0.026 4.113%
Share volume: 645,050
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.61
0.03
4.29%
Fundamental analysis
18%
Profitability
17%
Dept financing
34%
Liquidity
67%
Performance
4%
Performance
5 Days
-0.49%
1 Month
-20.08%
3 Months
-25.56%
6 Months
-52.61%
1 Year
-40.99%
2 Year
-48.31%
Key data
Stock price
$0.63
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.57 - $1.37
52 WEEK CHANGE
-$0.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: John Thero
Region: US
Website: http://www.amarincorp.com/
Employees: 647
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.amarincorp.com/
Employees: 647
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Recent news